Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Emergent Biosolutions (NYSE:EBS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.
Analyst Recommendations
This is a summary of current recommendations for Entrada Therapeutics and Emergent Biosolutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Emergent Biosolutions | 2 | 1 | 3 | 0 | 2.17 |
Entrada Therapeutics presently has a consensus price target of $17.75, indicating a potential upside of 157.25%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 42.41%. Given Entrada Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Emergent Biosolutions.
Insider & Institutional Ownership
Risk & Volatility
Entrada Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500.
Profitability
This table compares Entrada Therapeutics and Emergent Biosolutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -3,537.73% | -57.61% | -46.54% |
| Emergent Biosolutions | -22.95% | 16.35% | 6.17% |
Earnings and Valuation
This table compares Entrada Therapeutics and Emergent Biosolutions”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $25.42 million | 10.57 | -$143.75 million | ($3.96) | -1.74 |
| Emergent Biosolutions | $742.90 million | 0.48 | $52.60 million | ($3.55) | -1.98 |
Emergent Biosolutions has higher revenue and earnings than Entrada Therapeutics. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Entrada Therapeutics
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
About Emergent Biosolutions
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
